Pfizer (PFE) Cash from Financing Activities (2009 - 2026)
Pfizer (PFE) posted quarterly Cash from Financing Activities of -$2.9 billion for Q1 2026, up 45.36% year-over-year from -$2.0 billion in Q1 2025, and down 579.19% quarter-over-quarter from $596.0 million in Q4 2025.
Pfizer (PFE) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Cash from Financing Activities for 18 consecutive years, with -$2.9 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 45.36% year-over-year to -$2.9 billion; the TTM figure through Mar 2026 stood at -$7.9 billion (up 67.81% YoY), while the FY2025 annual figure was -$10.3 billion, up 39.88% from the prior year.
- Cash from Financing Activities declined to -$2.9 billion in Q1 2026 per PFE's latest filing, from $596.0 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $27.2 billion in Q3 2023 and bottomed at -$12.0 billion in Q3 2024.
- Historically, Cash from Financing Activities has averaged -$522.2 million across 5 years, with a median of -$2.8 billion in 2023.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 134.34% — and 2023, when it soared 978.33%.
- Pfizer's Cash from Financing Activities stood at $2.5 billion in 2022, then soared by 115.95% to $5.4 billion in 2023, then slumped by 320.98% to -$12.0 billion in 2024, then jumped by 104.96% to $596.0 million in 2025, then sank by 579.19% to -$2.9 billion in 2026.
- Business Quant data shows PFE's Cash from Financing Activities at -$2.9 billion in Q1 2026, $596.0 million in Q4 2025, and -$2.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -8.78 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -5.05 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.76 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -2.02 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -3.89 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -1.48 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 2.34 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -3.66 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -2.10 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -3.66 Bn |
| Jun 28, 2026 | -3.66 Bn |
| Mar 29, 2026 | -2.86 Bn |
| Mar 29, 2026 | -2.86 Bn |
| Dec 31, 2025 | 596.00 Mn |
| Dec 31, 2025 | 596.00 Mn |
| Sep 28, 2025 | -2.48 Bn |
| Sep 28, 2025 | -2.48 Bn |
| Jun 29, 2025 | -3.20 Bn |
| Jun 29, 2025 | -3.20 Bn |
| Mar 30, 2025 | -5.23 Bn |
| Mar 30, 2025 | -5.23 Bn |
| Sep 29, 2024 | -12.03 Bn |
| Sep 29, 2024 | -12.03 Bn |
| Jun 30, 2024 | -2.46 Bn |
| Jun 30, 2024 | -2.46 Bn |
| Mar 31, 2024 | -4.93 Bn |
| Mar 31, 2024 | -4.93 Bn |
| Dec 31, 2023 | 5.44 Bn |
| Dec 31, 2023 | 5.44 Bn |